Expanding access to a lifesaving, free COVID-19 treatment, Array Advisors helped launch the first private practice monoclonal antibody infusion center in Maryland. As the consulting team provides support to care sites across Maryland – expanding access to cutting edge COVID-19 treatments, among other aims—the opening in Gambrills marks another milestone.

Monoclonal Antibody Treatment Site Infusion Chairs

“The medicine has been shown to be tremendous in keeping people out of the hospital. It’s truly a lifesaving treatment,” says Dr. Ron Elfenbein, Medical Director and Founder of First Call Medical Center in Gambrills, Maryland. “We are thrilled to be part of offering people a treatment option for COVID-19 and thankful for the opportunity to bring this to our local community.”

The infusion center is located at 1425 Annapolis Rd., Odenton, MD 21113. The location expands access to the treatment within Anne Arundel County, offering a local alternative to the Baltimore Convention Center field hospital. The infusion center is one of 21 in the state.

The medicine is administered intravenously, infusion takes one hour and is followed by one hour of observation. To find out if you or a loved one is eligible for the treatment, call 443 459-1095 to speak with a clinician at First Call Medical Center between 8 a.m. – 5 p.m. Monday to Friday.

A second site led by First Call Medical Center will be opening in April at City of Praise Church. An integrated testing and treatment space opened in partnership with Health and Human Services and Maryland Department of Health, the site is located at 8500 Jericho City Drive, Landover MD 20785.

Beyond the infusion center in Gambrills, Array Advisors recently provided support to Adventist HealthCare’s Alternate Site in Takoma Park, MD, in its opening. The center provides monoclonal antibody infusions and is located at 7600 Carroll Avenue in a high-risk, underserved community.

Monoclonal antibody infusions are used to treat COVID-19 positive patients who are at high risk for hospitalization or decompensation. The treatment is intended for high-risk patients, is free of cost and can be lifesaving. Monoclonal antibody infusions can help hospitals retain capacity by keeping patients out of the inpatient setting or filling up emergency departments.

The FDA issued emergency use authorizations for three monoclonal antibody treatments, two in Nov. 2020, and one in Feb. 2021. Although it was widely expected that demand for treatment would outstrip supply, roughly 75 percent of the supply allocated to states remained as of March 2021. Learn more about the nationwide effort to expand access to monoclonal antibody treatment by reading the National Governors Association’s bulletin.